Indivior Pharmaceuticals, Inc. (SPUN)
| Market Cap | 4.28B |
| Revenue (ttm) | 1.37B +16.4% |
| Net Income | 450.00M +248.8% |
| EPS | 3.55 +250.9% |
| Shares Out | 118.04M |
| PE Ratio | 10.21 |
| Forward PE | 8.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,869,435 |
| Open | 35.43 |
| Previous Close | 35.37 |
| Day's Range | 35.32 - 37.02 |
| 52-Week Range | 27.68 - 42.81 |
| Beta | 1.13 |
| Analysts | Strong Buy |
| Price Target | 49.50 (+36.44%) |
| Est. Earnings | Nov 3, 2026 |
About SPUN
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet... [Read more]
Financial Performance
In 2025, Indivior Pharmaceuticals's revenue was $1.24 billion, an increase of 4.29% compared to the previous year's $1.19 billion. Earnings were $210.00 million, an increase of 2900.00%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for SPUN stock is "Strong Buy." The 12-month stock price target is $49.5, which is an increase of 36.44% from the latest price.
News
Indivior Pharmaceuticals Earnings release: Q3 2026
Indivior Pharmaceuticals released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Indivior Pharmaceuticals Quarterly report: Q3 2026
Indivior Pharmaceuticals has published its Q3 2026 quarterly earnings report on October 29, 2026.
Indivior Reports Third Quarter 2026 Financial Results
Q3'26 Total Net Revenue of $ 356 Million, Up 13% YoY Record Quarterly Total SUBLOCADE® Net Revenue of $ 267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $ 137 Million and Record Non-GAA...
Indivior to Report Third Quarter 2026 Financial Results
RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 202...
Indivior Pharmaceuticals Transcript: EGM 2026
Stockholders approved the common-stock issuance connected to the merger. As a result, the proposed adjournment vote was not needed.
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special ...
Indivior Pharmaceuticals Slides: Corporate presentation
Indivior Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 3, 2026.
Indivior Pharmaceuticals Earnings Call Transcript: Q2 2026
A merger of equals will create a CNS biopharma leader with $2.2B pro forma revenue, $888M adjusted EBITDA, and five key growth products. The deal brings $125M in annual cost synergies, a strong balance sheet, and significant firepower for future business development.
Indivior Pharmaceuticals Earnings release: Q2 2026
Indivior Pharmaceuticals released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Indivior Pharmaceuticals Slides: Q2 2026
Indivior Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
Indivior Pharmaceuticals Quarterly report: Q2 2026
Indivior Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 3, 2026.
Supernus, Indivior merge to strengthen neuroscience drug portfolio
Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that would create a company with about $2.2 billion in annual revenue and a portfolio of m...
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
• Q2'26 Total Net Revenue of $ 343 Million, Up 14% YoY • Record Quarterly Total SUBLOCADE® Net Revenue of $ 253 Million in Q2'26, Up 21% YoY • Record Quarterly GAAP Net Income of $122 Million an...
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
RICHMOND, Va., July 23, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026,...
Indivior Pharmaceuticals Transcript: Transcript
Indivior Pharmaceuticals Transcript: Transcript
Indivior Pharmaceuticals Transcript: Transcript
2024 results exceeded guidance, led by 20% Sublocade growth, but 2025 is forecast as a transition year with declining Suboxone Film revenue and flat Sublocade sales due to funding and competitive pressures. Cost reductions, litigation settlements, and focused R&D support long-term growth.
Indivior Pharmaceuticals Transcript: Transcript
Indivior Pharmaceuticals Transcript: Transcript
The session highlighted a strategic focus on SUBLOCADE growth, organizational simplification, and significant cost reductions, with a new operating model set for 2025-2026. Market share remains strong despite competition, and R&D is concentrated on two phase II assets, with further updates expected in early 2025.
Indivior Pharmaceuticals Transcript: Transcript
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-rele...
Indivior to Participate in Upcoming Investor Conferences
RICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: 2026 Jefferies Gl...
Indivior Announces $175 Million Accelerated Share Repurchase
RICHMOND, Va., May 04, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced that it has entered into a $175 million accelerated share repurchase agreement (“the ASR”...
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Q1'26 Total Net Revenue of $317 Million, Up 19% YoY Q1'26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and Q1'26 Non-GAAP Net Income of $123 Million Re...
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
RICHMOND, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), a leader in the treatment of opioid use disorder (OUD), will present one new scientific poster and coll...